Skip to main content
SP5007,674.37+0.43%DOW53,277.01+0.98%NASDAQ26,180.46+0.43%BTC$77,812.00+5.53%ETH$2,513.75+7.22%GOLD$4,661.60+1.97%OIL$86.64-0.22%
Smart Investors Daily
Sign InSign Up Free
CE

NASDAQ · CERC

Cerecor Inc.

Healthcare · Biotechnology

$2.93

Down-$0.05 (-1.68%)

Updated Aug 22, 2026, 2:39 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
38.63M
P/E ratio
-1.53
Dividend yield
0.00%
52-week range
— – —
Volume
258.59K
Avg. volume
639.17K

Price performance

CERC price history

1M range · 0 trading sessions · Daily adjusted prices

CERC does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest CERC news

The latest Smart Investors Daily articles mentioning CERC.

Stock researchCompany · Overview

CERC research

Overview

Company profile and research snapshot.

Company profile

Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803. The company is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of autoimmune inflammatory diseases, such as adult onset stills disease and multiple myeloma; CERC-006, a dual mTOR inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody for the treatment of Pediatric-onset Crohn's diseases. In addition, it develops CERC-913, a protide nucleotide for the treatment of mitochondrial disorder; CERC-005, a monoclonal antibody to treat rare auto-inflammatory diseases; CERC-301 for the treatment of symptomatic Orthostatic Hypotension; and CERC-406 for the treatment of Parkinson's disease. Further, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
CERC recent ratings
DateFirmRatingTarget
Jun 4, 2021Cantor FitzgeraldOverweight—
Apr 21, 2021Maxim GroupBuy—
Apr 20, 2021JefferiesBuy—
May 13, 2020OppenheimerOutperform—
Dec 2, 2019H.C. WainwrightBuy—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Aug 26, 2021

Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.

WAYNE, Pa. and ROCKVILLE, Md., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases announced today that it has launched its new corporate name Avalo Therapeutics, Inc. This new name reflects the Company’s dedication to helping address the significant unmet medical need for patients, as well as to align with the forward momentum of its large and promising pipeline of potential first-in-class therapeutic candidates. In conjunction with the corporate name change, the Company will trade on the Nasdaq Capital Market under the new ticker symbol "AVTX". The new ticker will become effective at the open of the market on August 26, 2021. In addition, the Company will launch a new website address: www.avalotherapeutics.com.

GlobeNewswire Inc. · Aug 2, 2021

Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance

Achieved performance milestone with positive initial results from its Phase 1b trial of CERC-002 in moderate-to- severe Crohn’s Disease who had previously failed three or more lines of biologics therapies, including anti-TNF alpha treatments Achieved performance milestone with positive initial results from its Phase 1b trial of CERC-002 in moderate-to- severe Crohn’s Disease who had previously failed three or more lines of biologics therapies, including anti-TNF alpha treatments

Benzinga · May 19, 2021

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers Lianluo Smart (NASDAQ:LLIT) stock rose 35.13% to $10.0 during Wednesday's regular session. Lianluo Smart's stock is trading at a volume of 4.6 million shares as of 12:30 EST. This is 988.15% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $48.5 million. Reata Pharmaceuticals (NASDAQ:RETA) stock rose 23.26% to $102.2. Trading volume for Reata Pharmaceuticals's stock is 2.0 million as of 12:30 EST. This is 613.89% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.7 billion. Advaxis (NASDAQ:ADXS) shares moved upwards by 21.3% to $0.59. Advaxis's stock is trading at a volume of 146.9 million shares as of 12:30 EST. This is 2202.68% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $81.2 million. Cerecor (NASDAQ:CERC) stock moved upwards by 12.02% to $2.54. As of 12:30 EST, this security is trading at ...Full story available on Benzinga.com

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By